The Association of Latvian Chemical and Pharmaceutical Industry (LAKIFA)



The Latvian R&I context and the contribution of RTOs

Vitalijs Skrivelis Chairman of the Board, LAKIFA

The Synergies with Research and Innovation Funds: Stairway to Excellence Riga, Latvia, 15.04.2015.





- Brief introduction Association of Chemical and Pharmaceutical Industry of Latvia and PharmIdea
- Innovation eco-system by eyes of manufacturer
- Private Public partnership as example of boosting contract research infrastructure for pharma and medical product innovation



The Association of Latvian Chemical and Pharmaceutical Industry



LAKIFA is steadily growing association, representing 50 companies and 9 industry sub-sectors:


- manufacturers of pharmaceuticals and active pharmaceutical ingredients
- phytochemicals
- manufacturers and distributors of cosmetics and household products
- distributors and manufacturers of chemical raw materials
- glass fiber production
- rubber manufacturer and plastic converters
- manufacturers and dealers of paints, coatings and building chemistry
- dealers of chemical equipment and reagents
- industrial gases production



The Association of Latvian Chemical and Pharmaceutical Industry

Membership and active international networking:

- The Latvian Confederation of Employers, LDDK
- Latvian Chamber of Commerce and Industry, LTRK
- European Council of Chemical Industry, CEFIC
- The European Cosmetic, Perfumery and Toiletry Association, Cosmetics Europe
- The European Detergents and Household Products Association, A.I.S.E.
- European Industrial Gases Association, EIGA
- European Chemicals Employers Group, ECEG







A · I · S · F









Leading pharma & biotech companies in Latvia



- **Grindeks** (synthetic drugs)
- Olainfarm (synthetic drugs)
- PharmIdea (sterile pharmaceuticals)
- Silvanols (phytochemicals, nature products)
- Virotherapy Center of Latvia (anticancer therapy of tumours by virus application)
- **OSI** (new drug research, medical chemistry)
- **BMC** (new drug research, medical chemistry)
- Nuclear medicine centre (cancer diognostics, new drug research)
- Biosan (laboratory & biotech equipment)

5

 Biotehniskais Centrs (laboratory & biotech equipment)
 Life Science Cluster of Latvia



PharmIdea

private pharmaceutical company





Main business activities

Development and manufacturing of own sterile generic hospital drugs in niche therapeutic areas for global pharmaceutical market since 2008:

- intensive care & reanimation
- hospital gynaecology
- anti-cancer



Innovative ideas and projects: hospital bacteriophages (alternative for antibiotics) and oncoviruses (alternative for chemotherapy drugs)




DEFINITIONS

- RESEARCH creation of knowledge
- INNOVATION transformation of knowledge into products demanded and accepted by market
 - RESERSH = scientists & INNOVATION = entrepreneurs





9






III For further growth of Latvia economy we need export-capable manufacturing industries

accordingly ---- Innovation eco-system by eyes of manufacturer

- Support of Industrial Applied Research via Competence Centre programm (80 m€, 2016.- 2021.)
- Support of start-up of manufacturing of new, innovative, export oriented products (100 m€, 2016.- 2021.)
- 3. Support of **training and education** for broad scope of industrial related technologies (20 m€, 2016.- 2021.)










Cancer patient in PET/CT scaning






Why till now have not been developed PET/CT Technology in Latvia?

- There should be **established 3 complex competencies** under integrative, discipline and specific control:
 - Radiochemistry (cyclotron = physics + chemistry + mechanic + software)
 - Sterile technologies under regulations of Good Manufacturing Practice (GMP)
 - Nuclear medicine (interpretation of images)
- Cyclotron and establishment of PET/CT center requires 9-12 m€ capital investments
- Weak public-private partnership culture in Latvia, especially for knowledge and technologicaly intensive projects



de facto Private – Public partnership project




Riga Nuclear Medicine Centre (NMC)

ambitions to introduce world class technology for cancer and neuro-degenerative research and diognostics in Latvia NUKLEĀRĀS MEDICĪNAS CENTRS Shareholders of NMC project


Private companies	Public partners
 V.Skrīvelis & team, 52% of shares : Competence in sterile technologies and radiochemistry Competence in Good Manufacturing Practice (GMP) certification Competence in radiochemistry and radiation safety Competence in management of ERDF co-funded laboratory's projects 	 Riga Stradins University (Medical academy), 47% of shares: Competence in medicine science industry, including gene expression technologies; Competence to train specialists of nuclear medicine Competence of cancer research (RSU Oncology Institute)
	 Latvian Institute of Organic Synthesis, 1,0% of shares: R&D capabilities in medicine chemistry and fine organic synthesis; Competences of the pharmaceutical research.







Cyclotron and PET/CT camera





NMC building progress, March 2015





I am working hard to say in near future:

DEAR CANCER, ONE DAY I HOPE YOU WILL BE JUST A ZODIAC SIGN



Chairman of the Board

Mr. Vitalijs Skrivelis lakifa@lakifa.lv

Managing Director

Ms. Raina Dureja rdureja@lakifa.lv

Address: Dzirnavu street 93, Riga, LV-1011, Latvia Tel: +371 67298683 Fax: +371 67298693 www.lakifa.lv





Thank you for your attention!

